APOL1 Bi- and Monoallelic Variants and Chronic Kidney Disease in West Africans

被引:0
|
作者
Gbadegesin, Rasheed A. [1 ]
Ulasi, Ifeoma [4 ]
Ajayi, Samuel [5 ]
Raji, Yemi [5 ]
Olanrewaju, Timothy [6 ]
Osafo, Charlotte
Ademola, Adebowale D. [5 ]
Asinobi, Adanze [5 ,10 ]
Winkler, Cheryl A. [19 ]
Burke, David [22 ]
Arogundade, Fatiu [7 ]
Ekem, Ivy [17 ]
Plange-Rhule, Jacob [18 ]
Mamven, Manmak [8 ]
Matekole, Michael [15 ]
Amodu, Olukemi [5 ]
Cooper, Richard [25 ]
Antwi, Sampson [18 ]
Adeyemo, Adebowale A. [20 ]
Ilori, Titilayo O. [26 ]
Adabayeri, Victoria [15 ]
Nyarko, Alexander [16 ]
Ghansah, Anita [16 ]
Amira, Toyin [9 ]
Solarin, Adaobi
Awobusuyi, Olugbenga [10 ]
Kimmel, Paul L. [21 ]
Brosius, Frank Chip [31 ]
Makusidi, Muhammad [11 ]
Odenigbo, Uzoma [12 ]
Kretzler, Matthias [23 ]
Hodgin, Jeffrey B. [24 ]
Pollak, Martin R. [27 ,28 ]
Boima, Vincent [15 ]
Freedman, Barry I. [2 ]
Palmer, Nicholette D. [3 ]
Collins, Bernard [29 ]
Phadnis, Milind [32 ]
Smith, Jill [32 ]
Agwai, Celia I. [33 ]
Okoye, Ogochukwu [13 ]
Abdu, Aliyu [14 ]
Wilson, Jillian [33 ]
Williams, Winfred [28 ,30 ]
Salako, Babatunde L. [5 ]
Parekh, Rulan S. [34 ,35 ]
Tayo, Bamidele [25 ]
Adu, Dwomoa [15 ]
Ojo, Akinlolu [33 ]
机构
[1] Duke Univ, Med Ctr, Dept Pediat, Durham, NC USA
[2] Wake Forest Univ Sch Med, Dept Med, Winston Salem, NC USA
[3] Wake Forest Univ Sch Med, Dept Biochem, Winston Salem, NC USA
[4] Univ Nigeria, Dept Med, Nsukka, Nigeria
[5] Univ Ibadan, Coll Med, Dept Med, Ibadan, Nigeria
[6] Univ Ilorin, Dept Med, Ilorin, Nigeria
[7] Obafemi Awolowo Univ, Dept Med, Ife, Nigeria
[8] Univ Abuja, Dept Med, Abuja, Nigeria
[9] Univ Lagos, Coll Med, Dept Med, Lagos, Nigeria
[10] Lagos State Univ, Coll Med, Dept Med, Ojo, Nigeria
[11] Usmanu Danfodiyo Univ, Dept Med, Sokoto, Nigeria
[12] Nnamdi Azikiwe Univ, Teaching Hosp, Nnewi, Nigeria
[13] Delta State Univ, Teaching Hosp, Oghara, Nigeria
[14] Aminu Kano Teaching Hosp, Kano, Nigeria
[15] Univ Ghana, Med Sch, Dept Med, Accra, Ghana
[16] Univ Ghana, Noguchi Mem Inst Med Res, Accra, Ghana
[17] Univ Cape Coast, Dept Med, Cape Coast, Ghana
[18] Kwame Nkrumah Univ Sci & Technol, Kumasi, Nigeria
[19] NCI, Basic Res Lab, Frederick Natl Lab Canc Res, Frederick, MD USA
[20] Natl Human Genome Res Inst, NIH, Ctr Res Genom & Global Hlth, Bethesda, MD USA
[21] Natl Inst Diabet & Digest Kidney Dis, Div Kidney Urol & Digest Dis, NIH, Bethesda, MD USA
[22] Univ Michigan, Med Sch, Dept Human Genet, Ann Arbor, MI USA
[23] Univ Michigan, Dept Med, Med Sch, Ann Arbor, MI USA
[24] Univ Michigan, Med Sch, Dept Pathol, Ann Arbor, MI USA
[25] Loyola Univ, Parkinson Sch Hlth Sci & Publ Hlth, Chicago, IL USA
[26] Boston Univ, Sch Med, Dept Med, Boston, MA USA
[27] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA
[28] Harvard Med Sch, Boston, MA USA
[29] Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA
[30] Massachusetts Gen Hosp, Dept Med, Boston, MA USA
[31] Univ Arizona, Coll Med, Dept Med, Tucson, AZ USA
[32] Univ Kansas, Med Ctr, Dept Biostat & Data Sci, Kansas City, KS USA
[33] Univ Kansas, Med Ctr, Dept Med, Kansas City, KS USA
[34] Hosp Sick Children, Womens Coll Hosp, Dept Med & Pediat, Toronto, ON, Canada
[35] Univ Toronto, Toronto, ON, Canada
关键词
FOCAL SEGMENTAL GLOMERULOSCLEROSIS; RISK VARIANTS; NEPHROPATHY; PROGRESSION; GENE; PREVALENCE; ASSOCIATE; RACE; MYH9; CKD;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Apolipoprotein L1 gene ( APOL1 ) variants are risk factors for chronic kidney disease (CKD) among Black Americans. Data are sparse on the genetic epidemiology of CKD and the clinical association of APOL1 variants with CKD in West Africans, a major group in the Black population. METHODS We conducted a case-control study involving participants from Ghana and Nigeria who had CKD stages 2 through 5, biopsy-proven glomerular disease, or no kidney disease. We analyzed the association of CKD with APOL1 variants among participants with high-risk genotypes (two APOL1 risk alleles) and those with low-risk genotypes (fewer than two APOL1 risk alleles) by fitting logistic-regression models that controlled for covariates, including clinical site, age, and sex. RESULTS Among 8355 participants (4712 with CKD stages 2 through 5, 866 with glomerular diseases, and 2777 with no kidney disease), the prevalence of monoallelic APOL1 variants was 43.0% and that of biallelic APOL1 variants was 29.7%. Participants with two APOL1 risk alleles had higher odds of having CKD than those with one risk allele or no risk alleles (adjusted odds ratio, 1.25; 95% confidence interval [CI], 1.11 to 1.40), as well as higher odds of focal segmental glomerulosclerosis (adjusted odds ratio, 1.84; 95% CI, 1.30 to 2.61). Participants with one APOL1 risk allele had higher odds of having CKD than those with no risk alleles (adjusted odds ratio, 1.18; 95% CI, 1.04 to 1.33), as well as higher odds of focal segmental glomerulosclerosis (adjusted odds ratio, 1.61; 95% CI, 1.04 to 2.48). The inclusion of covariates did not modify the association of monoallelic and biallelic APOL1 variants with CKD or focal segmental glomerulosclerosis. CONCLUSIONS In this study, monoallelic APOL1 variants were associated with 18% higher odds of CKD and 61% higher odds of focal segmental glomerulosclerosis; biallelic APOL1 variants were associated with 25% higher odds of CKD and 84% higher odds of focal segmental glomerulosclerosis. (Funded by the National Human Genome Research Institute and others.)
引用
收藏
页数:11
相关论文
共 50 条
  • [21] The Mechanism of Kidney Disease Due to APOL1 Risk Variants
    Pays, Etienne
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 31 (11): : 2502 - 2505
  • [22] APOL1 risk variants drive kidney disease in mice
    Susan J. Allison
    Nature Reviews Nephrology, 2017, 13 : 259 - 259
  • [23] APOL1 Kidney Risk Variants and Proteomics
    Chen, Teresa K.
    Surapaneni, Aditya L.
    Arking, Dan E.
    Ballantyne, Christie M.
    Boerwinkle, Eric
    Chen, Jingsha
    Coresh, Josef
    Koettgen, Anna
    Susztak, Katalin
    Tin, Adrienne
    Yu, Bing
    Grams, Morgan E.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 17 (05): : 684 - 692
  • [24] Effect of APOL1 disease risk variants on APOL1 gene product
    Haque, Shabirul
    Patil, Gauri
    Mishra, Abheepsa
    Lan, Xiqian
    Popik, Waldemar
    Malhotra, Ashwani
    Skorecki, Karl
    Singhal, Pravin C.
    BIOSCIENCE REPORTS, 2017, 37
  • [25] Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants
    Egbuna, Ogo
    Zimmerman, Brandon
    Manos, George
    Fortier, Anne
    Chirieac, Madalina C.
    Dakin, Leslie A.
    Friedman, David J.
    Bramham, Kate
    Campbell, Kirk
    Knebelmann, Bertrand
    Barisoni, Laura
    Falk, Ronald J.
    Gipson, Debbie S.
    Lipkowitz, Michael S.
    Ojo, Akinlolu
    Bunnage, Mark E.
    Pollak, Martin R.
    Altshuler, David
    Chertow, Glenn M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (11): : 969 - 979
  • [26] APOL1 variants and kidney disease in people of recent African ancestry
    Giulio Genovese
    David J. Friedman
    Martin R. Pollak
    Nature Reviews Nephrology, 2013, 9 : 240 - 244
  • [27] APOL1 variants and kidney disease in people of recent African ancestry
    Genovese, Giulio
    Friedman, David J.
    Pollak, Martin R.
    NATURE REVIEWS NEPHROLOGY, 2013, 9 (04) : 240 - 244
  • [28] Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans
    Genovese, Giulio
    Friedman, David J.
    Ross, Michael D.
    Lecordier, Laurence
    Uzureau, Pierrick
    Freedman, Barry I.
    Bowden, Donald W.
    Langefeld, Carl D.
    Oleksyk, Taras K.
    Knob, Andrea L. Uscinski
    Bernhardy, Andrea J.
    Hicks, Pamela J.
    Nelson, George W.
    Vanhollebeke, Benoit
    Winkler, Cheryl A.
    Kopp, Jeffrey B.
    Pays, Etienne
    Pollak, Martin R.
    SCIENCE, 2010, 329 (5993) : 841 - 845
  • [29] APOL1 Variants From Parasites to Kidney Function to Cardiovascular Disease
    Reiner, Alex P.
    Susztak, Katalin
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 (02) : 219 - 220
  • [30] APOL1 Variant and Kidney Disease
    Hilliard, Constance B.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 332 (12):